AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01577368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam intermittent infusion
Description: Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
Study NCT00987350 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Trivalent Influenza Vaccine
Description: Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
Study NCT00825682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology treatment.
Description: Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
Study NCT03680560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTR T Cell Product
Description: Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
Study NCT03680560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: monoclonal antibody targeting HER2
Study NCT00115739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
Study NCT01991860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421- Amisulpride for IV injection
Description: APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
Study NCT01991860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
Study NCT03900442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-100
Description: Doses of 500 to 2000 mg/m2 will be administered.
Study NCT02930330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INT
Description: * 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test.
Study NCT02930330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONT
Description: * 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test.
Study NCT02930330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONT
Description: * 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test.
Study NCT04035499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO-EXCAP Mobile App
Description: A mobile app delivery platform and the EXCAP©® exercise program
Study NCT01381263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural medicine treatment
Description: The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
Study NCT01381263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
Study NCT01643356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention to reduce excess weight gain during pregnancy
Description: Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
Study NCT03555032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Description: One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
Study NCT04087265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transabdominal ultrasound
Description: Transabdominal ultrasound will be performed 30 minutes before colonoscopy
Study NCT04608929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel exercise-focused interventions
Description: After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
Study NCT04608929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit and scale evaluations
Description: After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
Study NCT02281201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BE1116 (Prothrombin Complex Concentrate)
Study NCT03320291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regjoint
Description: Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
Study NCT04325594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheterization
Description: Catheterization of the right and left heart cavities
Study NCT04325594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Description: Catheterization of the right and left heart cavities
Study NCT04325594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells
Description: After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute
Study NCT01727050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin sealant spray
Description: Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
Study NCT01727050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stapling
Description: Fixation of mesh would be performed using mechanical staplers
Study NCT06388330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low FODMAP diet
Description: strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
Study NCT02289482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB (SDD)
Description: GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
Study NCT02289482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB (API)
Description: GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
Study NCT02289482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
Study NCT02289482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
Study NCT01621152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional management arm
Description: Based on KDIGO guidelines and as per primary physician in the ICU
Study NCT01621152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AKI sniffer instigated AKI management
Description: After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
Study NCT01934894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Study NCT01934894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Study NCT01600768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Lactams
Description: infusion time: 30 mins or 1 hr
Study NCT01600768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Lactams
Description: infusion time 4 hrs
Study NCT01324622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminoplasty
Description: Utilizing the ARCH Fixation System (Study device)
Study NCT01324622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy
Description: standard procedure
Study NCT00913718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Study NCT00913718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Study NCT02777684 — intervention group
Intervention type: OTHER
Intervention: Qualitative study
Study NCT01585935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFLIPID
Description: target dose: 3g/kg/d
Study NCT01585935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INTRALIPID
Description: target dose: 3g/kg/d
Study NCT03288493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-BCMA-101 CAR-T cells
Description: P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated.
Study NCT03288493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.
Study NCT03684291 — intervention group
Intervention type: PROCEDURE
Intervention: Mode of Mechanical Ventilation
Description: Adjustment of mechanical ventilation mode
Study NCT04536519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteoarthritis management
Description: The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups.
Study NCT04456218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCKU-scope-01 (a custom-made biliary endoscope system)
Description: The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
Study NCT00929266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous injection of labeled cRBC
Description: This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
Study NCT00461708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg, PO, once per day
Study NCT00461708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
Study NCT02065219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
Study NCT02065219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
Study NCT02870426 — intervention group
Intervention type: PROCEDURE
Intervention: Frontal Craniotomy and retrieval of OBs
Description: For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
Study NCT02870426 — intervention group
Intervention type: PROCEDURE
Intervention: OB Retrieval During Anterior Cranial Surgery
Description: Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
Study NCT03817580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Project X 26ml
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study NCT03817580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Project X 5.1ml
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study NCT03817580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevantics Maxi Swabstick
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study NCT03140111 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LAMELLEYE
Description: Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
Study NCT03140111 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OPTIVE FUSION
Description: Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
Study NCT01428791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generations older adult membership program
Description: Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops.
Study NCT03758482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Probe meal
Description: The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
Study NCT00383214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epratuzumab
Description: 360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
Study NCT00479388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: simvastatin
Description: simvastatin (20mg to 40mg) for 12 weeks.
Study NCT00479388 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: niacin (+) laropiprant
Description: One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
Study NCT00479388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin calcium
Description: atorvastatin calcium (20mg to 40mg) for 12 weeks.
Study NCT01909128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented milk
Description: fermented milk with Lactobacillus CBA-L74
Study NCT01909128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented rice
Description: fermented rice wit Lactobacillus CBA-L74
Study NCT02743728 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Anatomical and Diffusion Tensor Imaging Analysis.
Study NCT00383214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT04243356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Encounter Group
Description: Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
Study NCT02743728 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Assessment of brain (cortical) excitability
Study NCT02743728 — intervention group
Intervention type: BEHAVIORAL
Intervention: General Movement Assessment
Description: Spontaneous movement assessment of infant while lying in unperturbed state.
Study NCT00528268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (NaPB)
Description: The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
Study NCT03887416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG Oral Tablet [Farxiga]
Description: The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)
Study NCT03887416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Study NCT01694017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
Study NCT01694017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
Study NCT02904499 — intervention group
Intervention type: DRUG
Intervention: Dabigatran